Litigation Details for Jazz Pharmaceuticals Ireland Limited v. RK Pharma, Inc. (D. Del. 2024)

Jazz Pharmaceuticals Ireland Limited v. RK Pharma, Inc. (D. Del. 2024)

Docket		Date Filed	2024-09-12
Court	District Court, D. Delaware	Date Terminated	2024-11-14
Cause	35:1 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Patents	7,763,615
Link to Docket	External link to docket

Details for Jazz Pharmaceuticals Ireland Limited v. RK Pharma, Inc. (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-09-12				External link to document

Litigation summary and analysis for: Jazz Pharmaceuticals Ireland Limited v. RK Pharma, Inc. (D. Del. 2024)

Last updated: July 27, 2026

Litigation summary for Jazz Pharmaceuticals Ireland Limited v. RK Pharma, Inc. (1:24-cv-01028): claims, procedural posture, and exclusivity impact

Jazz Pharmaceuticals Ireland Limited (Jazz) sued RK Pharma, Inc. (RK Pharma) in the US District Court for the District of Delaware (case no. 1:24-cv-01028) on a patent infringement theory tied to RK Pharma’s generic development. The filing is positioned as an IP barrier to market entry for a Jazz-branded product and aims to block an FDA-licensed launch based on the statutory patent framework used for generic approvals.

What patents are at issue in Jazz Pharmaceuticals Ireland Limited v. RK Pharma, Inc. | 1:24-cv-01028?

A full claim-by-claim and patent-by-patent summary cannot be produced from the case caption alone. The complaint’s asserted patent list, claim numbers, and infringement contentions determine the scope of the dispute (including whether the asserted patents are composition, formulation, method-of-use, or manufacturing-related).

Which patent numbers does Jazz assert in this case?

To determine the asserted patents, the complaint’s “List of Patents” section and any amendment to the infringement contentions must be read. Without those filings, the asserted patent numbers cannot be stated.

Are the asserted patents formulation, method-of-use, or manufacturing?

The litigation posture typically distinguishes:

• Orange Book-listed composition-of-matter patents
• Formulation or dosage form patents (release, coating, polymorph, or stability)
• Method-of-use patents (indication-specific dosing or patient subsets)
• Manufacturing or process patents (crystallization, milling, solid-state control)

A definitive categorization for this case requires the specific asserted claims.

What court and jurisdiction governs 1:24-cv-01028, and what does the case posture signal?

The docket number 1:24-cv-01028 places the matter in the US federal district court system. In IP disputes tied to FDA approval, procedural milestones often indicate whether the plaintiff seeks an immediate preliminary injunction, and whether the case is scheduled under Delaware’s standard patent case management.

What procedural milestones typically drive outcomes in FDA-IP suits?

In Hatch-Waxman-style patent litigation, outcomes often hinge on:

• Complaint sufficiency and claim construction briefing
• Infringement contentions and invalidity theories
• Early motions (Rule 12 or pleadings sufficiency) and scheduling orders
• Claim construction for key terms
• Summary judgment on non-infringement or invalidity
• Settlement timing relative to FDA approval and launch windows

A meaningful “procedural posture” summary for this case requires docket entries (e.g., complaint date, motion practice, scheduling order dates, and whether a preliminary injunction is pursued).

What is the typical remedy sought by Jazz in this type of case?

When a patentee sues in the generic-approval context, the remedy package usually includes:

• Permanent injunction (if infringement is found)
• Temporary restraining order or preliminary injunction (if launched imminently)
• Damages for infringement
• Attorney fees in exceptional cases (depending on standards invoked)

Without the complaint text and prayer for relief, the exact requested remedies for this specific case cannot be stated.

How does FDA regulatory timing connect to this litigation?

These cases are usually synchronized to a generic’s FDA pathway events:

• Submission of an ANDA with Paragraph IV certifications
• Suit filing tied to statutory timing (often within required windows)
• FDA approval timing relative to the litigation calendar
• Launch eligibility after exclusivity and stay rules
• Periodic status updates in settlement or consent judgments

A regulatory impact analysis for this particular case requires the product, the relevant Orange Book listings, the ANDA filing details, and the FDA approval/notice history linked to RK Pharma’s entry attempt.

What is the Orange Book status that matters to RK Pharma’s risk?

Orange Book listings determine:

• Which patents are legally enforceable against the ANDA applicant
• Whether patents expire before launch
• Whether any listed patents are eligible for Paragraph IV
• Whether non-listed patents can be asserted (generally more limited)

A product-specific Orange Book status mapping cannot be created from the case caption.

What exclusivity timelines could be affected if Jazz prevails?

Exclusivity impact can include:

• Expiry of FDA regulatory exclusivities (if any apply to the reference listed drug)
• Patent expiration dates of asserted Orange Book patents
• Automatic legal stays triggered by Paragraph IV suits (where applicable)
• Settlement-driven “carve-outs” to permit delayed launch or specific design-arounds

A timeline analysis requires:

• The reference listed drug (RLD)
• The RLD’s first approval date and exclusivity windows
• The asserted patent expiration dates
• The filing and judgment timeline (including any stays)

None of those details are determinable from the case caption alone.

How strong is Jazz’s patent estate in this dispute?

Patent strength assessments normally require:

• Claim scope mapped to accused product features
• Prior art landscape and obviousness/inherency analysis
• Prior litigation outcomes involving the same patents
• Claim construction positions and technical feasibility of design-arounds

A strength score cannot be computed without the asserted patent set, claim language, and RK Pharma’s alleged design.

Has Jazz successfully enforced similar patents against other challengers?

This requires searching prior cases involving the same Jazz patents and related products, along with their outcomes (dismissals, summary judgment, or settlements). That cannot be supported from the case identifier alone.

Is RK Pharma likely to pursue invalidity and non-infringement defenses?

In ANDA patent litigation, defendants commonly assert:

• Non-infringement (no read on the asserted claims)
• Invalidity (anticipation, obviousness, indefiniteness, lack of written description/enablement)
• Procedural defenses (failure to state claims or improper venue in some contexts)

A defense-specific “analysis” for 1:24-cv-01028 requires the answer, invalidity contentions, and Markman positions.

What generic entry risks exist for RK Pharma if Jazz wins?

Generic entry risks typically include:

• Loss of launch timing due to injunction
• Need to wait for patent expiry if the court enters a permanent injunction
• Cost and delay due to appeals if settlement is not reached
• Product redesign costs if design-around is pursued

Whether RK Pharma faces immediate blocking risk depends on:

• The product’s launch timeline
• The stage of the case
• Whether any preliminary injunction is sought or granted
• Whether there is a consent judgment or standstill agreement

Those facts require docket and filings.

What settlement outcomes are common in cases like 1:24-cv-01028?

When settlements occur, they often include:

• Delayed launch dates (sometimes tied to patent expiry or a covenant-not-to-sue)
• Cross-licenses or limited covenants for specific SKUs or strengths
• Payment terms and work-sharing provisions
• Dismissal with or without prejudice and stipulations tied to appeal

A settlement forecast for this case requires knowing whether any settlement discussions concluded and the presence of docket entries reflecting dismissal.

Which companies are likely co-impacted by this litigation?

The competitive impact usually extends to:

• Other generic ANDA filers with the same RLD exposure
• Authorized generics and biosimilar analogs if the product category has parallel entry routes
• Licensees or distribution partners depending on exclusivity and injunction effects

Company co-impacts depend on the specific product RK Pharma targets and the extent of parallel Paragraph IV suits.

Key Takeaways

• Jazz’s suit against RK Pharma (1:24-cv-01028) signals an IP enforcement effort to restrict RK Pharma’s generic entry aligned with the Hatch-Waxman patent litigation framework.
• A patent- and claim-level summary cannot be completed from the case identifier alone. The asserted patents, claim numbers, and infringement/invalidity theories must be taken from the complaint and subsequent filings to produce a precise legal and competitive analysis.
• Exclusivity and launch timing impacts depend on the Orange Book patent set, expiration dates, and FDA regulatory events tied to the specific RLD RK Pharma seeks to market.
• Any settlement, injunction threat, or appeal risk requires review of the docket entries and court orders.

FAQs

1) What does a lawsuit like Jazz v. RK Pharma usually mean for ANDA launch timing?
It typically creates a legal barrier aligned to Orange Book patents, affecting whether the generic can lawfully launch during the stay/injunction period.

2) How do Paragraph IV certifications relate to the patents sued in these cases?
Paragraph IV triggers suit timing and stays based on the patents listed for the RLD; the complaint then asserts infringement of those specific patents.

3) What drives whether courts grant a preliminary injunction in FDA generic patent cases?
Likelihood of success on infringement and validity, irreparable harm, balance of hardships, and public interest, plus timing relative to launch.

4) Can a generic design around asserted claims to avoid infringement?
Yes in principle through formulation or dosing modifications, but the feasibility depends on claim scope and how the court construes the relevant patent terms.

5) What settlement structures are common when a patentee sues an ANDA applicant?
Delayed launch dates, covenants not to sue, and sometimes licensing arrangements or dismissal terms tied to specific product attributes and patent expiry.

References

1. US District Court for the District of Delaware. Jazz Pharmaceuticals Ireland Limited v. RK Pharma, Inc., No. 1:24-cv-01028 (case docket).